XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
"Analyst error" is not a root cause — it is a conclusion in search of evidence, and FDA’s May 2022 Level 2 revised OOS guidance is explicit that attributing an out-of-specification result to analyst
View details →
More than half of the small molecule drugs approved by FDA in any given year contain at least one stereocenter. For most of those programs, the enantiomeric impurity is not just a quality parameter
View details →
An FDA investigator reviewing your CAPA system is not interested in how many CAPAs you have opened — they are interested in how many you have closed with demonstrated effectiveness, and the gap between
View details →
CareFusion 213, LLC, a subsidiary of Becton, Dickinson and Company (BD), has recalled two configurations of its BD ChloraPrep One-Step and FREPP Clear sterile antiseptic applicators (2% w/v chlorhexidine gluconate and 70% v/v isopropyl
View details →
Most pharmaceutical quality risk assessments are produced in response to a regulatory request rather than to support a genuine decision — and the difference is immediately visible to an FDA reviewer who reads dozens
View details →
A drug substance that exists as multiple crystalline forms — differing in lattice structure, thermodynamic stability, and solubility — is not an unusual compound. It is the majority of small molecule APIs. The regulatory
View details →
Salt selection is the first CMC decision that determines whether your drug will be manufacturable, stable, and bioavailable — and it is a decision made before most of the regulatory framework that will eventually
View details →
The most consequential decisions during an FDA inspection are not made in the laboratory or on the manufacturing floor — they are made in the first two hours in the front room, when the
View details →
The starting material designation in a drug substance synthesis is one of the highest-stakes decisions in small molecule CMC development — and it is made years before the NDA submission by chemists who may
View details →
Every pharmaceutical conference in the past two years has featured a presentation claiming that AI will transform CMC development and regulatory review — almost none of them have explained which specific AI applications are
View details →
On June 2, 2026, FDA issued Warning Letter 320-26-91 to Umendra Life Sciences Private Limited, an OTC drug product manufacturer located in Bavla, Ahmedabad, Gujarat, India, citing systemic failures in incoming component testing and
View details →
On June 5, 2026, FDA issued Warning Letter 320-26-94 to Sante Manufacturing Inc., an over-the-counter drug product manufacturer located at 516 John Street N, Aylmer, Ontario, Canada. The letter, issued by the Center for
View details →
"The answer 'the excipient complies with USP/EP' satisfies the basic identification and quality requirement in 3.2.P.4 — and it is the answer that generates the follow-up deficiency 'please provide the functional characterization data and
View details →
Laboratory controls 483 observations are the most frequently issued citation category in FDA drug manufacturing inspections — and they are almost always rooted in the same two failures: OOS investigation protocols that stop short
View details →
The drug product specification is not complete because it passes internal review. It is complete when it addresses every critical quality attribute identified in P.2, when every method is validated to detect what it
View details →
FDA equipment and facilities 483 observations are rarely about whether the equipment works — they are almost always about whether the documentation demonstrates that the equipment has been qualified, maintained, and cleaned in a
View details →
Sections 3.2.P.5.4, 5.5, and 5.6 are where the drug product specification is tested against reality. The batch analysis data must demonstrate that the process reliably meets the specification; the impurity discussion must account for
View details →
On June 15, 2026, FDA issued Warning Letter 320-26-95 to Huons Co., Ltd., a drug manufacturing facility located at 100 Bio Valley-ro, Jecheon, Chungcheongbuk, South Korea, citing systemic data integrity violations following an inspection
View details →